SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth,” said Marc Stapley, Veracyte’s chief executive officer. “This strong result, combined with Afirma volume meeting our expectations and the res
Related Questions
How does the reported >25% YoY volume growth for Decipher compare to growth rates of similar diagnostic platforms in the industry?
Will the continued strong volume growth for Decipher lead to any changes in Veracyte's guidance for the full fiscal year 2025?
What is the potential impact of the Q2 results on institutional and retail analyst sentiment toward Veracyte?
What is the expected impact of the Q2 2025 results on Veracyte's share price in the short term?
What is the market's perception of Veracyte's growth trajectory relative to competitors such as Guardant Health and Illumina?
How does Veracyte's Q2 testing volume growth compare to its historical performance and recent trends?
What are the revenue and profit margin implications of the sustained Decipher growth and Afirma's performance?
Are there any operational or supply-chain constraints that could limit the scalability of Decipher and Afirma testing volumes?
What are the risks or upside scenarios if Veracyte fails to meet its projected volume growth targets for the remainder of 2025?
How might the sustained >25% YoY growth for Decipher influence future pricing, reimbursement, or partnership negotiations?